Piper Sandler Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $159
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has upgraded Neurocrine Biosciences to Overweight and increased its price target from $131 to $159, indicating a positive outlook for the company's stock.
August 29, 2024 | 9:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has upgraded Neurocrine Biosciences to Overweight and increased its price target from $131 to $159, suggesting a positive short-term impact on the stock price.
The upgrade from Neutral to Overweight by Piper Sandler, along with a significant increase in the price target, indicates strong confidence in Neurocrine Biosciences' future performance. This is likely to attract investor interest and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100